ReviewCurrent neuropharmacology2021
Therapeutic Potential of Ultrasound Neuromodulation in Decreasing Neuropathic Pain: Clinical and Experimental Evidence.
Review in Current neuropharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Review
- Neuromodulation Techniques Alleviating Neuropathic Pain by Targeting Microglia: A Narrative Review.Pain and therapy · 2026Review
- Emerging Nonpharmacologic Analgesic Technologies in Anesthesia: Mechanisms, Evidence, and Future Directions for Pharmacologic Alternatives.Biomedicines · 2026Review
- Therapeutic effects and potential mechanisms of focused ultrasound in neuropathic pain: a narrative review of preclinical studies.European journal of medical research · 2025Review
- Ultrasound-Guided Interventions for Neuropathic Pain: A Narrative Pictorial Review.Life (Basel, Switzerland) · 2025Review
- An overview of the non-procedural treatment options for peripheral neuropathic pain.Muscle & nerve · 2025Review
- Modulating neuroplasticity for chronic pain relief: noninvasive neuromodulation as a promising approach.Experimental & molecular medicine · 2025Review
- A Physiological Marker for Deep Brain Ultrasonic Neuromodulation.Neuromodulation : journal of the International Neuromodulation Society · 2025Article
- Hydrogels in wearable neural interfaces.Med-X · 2024Review
- Central and peripheral mechanisms of pain in fibromyalgia: scoping review protocol.Rheumatology international · 2023Article
- Transcranial Magneto-Acoustic Stimulation Attenuates Synaptic Plasticity Impairment through the Activation of Piezo1 in Alzheimer's Disease Mouse Model.Research (Washington, D.C.) · 2023Article
- Intensity-adjustable pain management with prolonged duration based on phase-transitional nanoparticles-assisted ultrasound imaging-guided nerve blockade.Journal of nanobiotechnology · 2022Article
- Potential Goals, Challenges, and Safety of Focused Ultrasound Application for Central Nervous System Disorders.Current neuropharmacology · 2022Article
- Advances in imaging technologies for the assessment of peripheral neuropathies in rheumatoid arthritis.Rheumatology international · 2021Review
- Neuromodulation of the Response to Neuropathic Pain in Chronic Diseases.Current neuropharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor more than seven decades, ultrasound has been used as an imaging and diagnostic tool. Today, new technologies, such as focused ultrasound (FUS) neuromodulation, have revealed some innovative, potential applications. However, those applications have been barely studied to deal with neuropathic pain (NP), a cluster of chronic pain syndromes with a restricted response to conventional pharmaceuticals.
objectiveTo analyze the therapeutic potential of low-intensity (LIFUS) and high-intensity (HIFUS) FUS for managing NP.
methodsWe performed a narrative review, including clinical and experimental ultrasound neuromodulation studies published in three main database repositories. DISCUSSION: Evidence shows that FUS may influence several mechanisms relevant for neuropathic pain management such as modulation of ion channels, glutamatergic neurotransmission, cerebral blood flow, inflammation and neurotoxicity, neuronal morphology and survival, nerve regeneration, and remyelination. Some experimental models have shown that LIFUS may reduce allodynia after peripheral nerve damage. At the same time, a few clinical studies support its beneficial effect on reducing pain in nerve compression syndromes. In turn, Thalamic HIFUS ablation can reduce NP from several etiologies with minor side-effects, but some neurological sequelae might be permanent. HIFUS is also useful in lowering non-neuropathic pain in several disorders.
conclusionAlthough an emerging set of studies brings new evidence on the therapeutic potential of both LIFUS and HIFUS for managing NP with minor side-effects, we need more controlled clinical trials to conclude about its safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.